Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.49 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.49 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.49 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.49 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.49 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12370800 | 0.94 | HRH3 (0.53) | L3MBTL1LMNAMAPTCYP4F2CYP4A11 | |
| SCHEMBL22922181 | 0.92 | CYP4F2 (0.59) | LMNAMAPTCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL7756814 | 0.91 | FFAR1 (0.53) | L3MBTL1LMNAMAPTCYP4F2CYP4A11 | |
| SCHEMBL1550285 | 0.90 | FFAR1 (0.69) | L3MBTL1LMNAMAPTFFAR1KMT2A | |
| SCHEMBL15080669 | 0.90 | CYP4F2 (0.49) | L3MBTL1LMNAMAPTCYP4F2CYP4A11 | |
| SCHEMBL1928824 | 0.89 | PLAAT3 (0.51) | L3MBTL1LMNAMAPTCYP4F2CYP4A11 | |
| SCHEMBL15679198 | 0.87 | FFAR1 (0.60) | L3MBTL1LMNAMAPTALDH1A1FFAR1 | |
| Methyl 3-Phenylpropanoate SCHEMBL27822992 | 0.87 | TDP1 (0.59) | L3MBTL1LMNAMAPTALDH1A1TDP1 | |
| SCHEMBL18657080 | 0.87 | CYP4Z1 (0.49) | CYP4F2CYP4A11TDP1PLAAT3PLAAT5 | |
| SCHEMBL16672973 | 0.85 | HPGD (0.50) | CYP4F2CYP4A11TDP1PLAAT3PLAAT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115197036-B | Method for performing anti-mahalanobis hydrogen carboxylation reaction on photocatalytic olefin compound and carbon dioxide | 中国科学院理化技术研究所 | 2024-01-23 | — | — | CN | disclosed |
| WO-2023158976-A1 | BORON-CONTAINING CYCLIC EMISSIVE COMPOUNDS AND COLOR CONVERSION FILM CONTAINING THE SAME | NITTO DENKO CORPORATION (JP) | 2023-08-24 | — | — | WO | disclosed |
| CN-115197036-A | Method for carrying out anti-Ma hydrocarboxylation reaction on olefin compound and carbon dioxide by photocatalysis | 中国科学院理化技术研究所 | 2022-10-18 | — | — | CN | disclosed |
| US-20220162374-A1 | EPOXY RESIN, EPOXY RESIN COMPOSITION, EPOXY RESIN CURED PRODUCT AND COMPOSITE MATERIAL | RESONAC CORPORATION (JP) | 2022-05-26 | — | — | US | disclosed |
| US-20200262969-A1 | EPOXY RESIN, EPOXY RESIN COMPOSITION, EPOXY RESIN CURED PRODUCT, AND COMPOSITE MATERIAL | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2020-08-20 | — | — | US | disclosed |
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | disclosed |
| US-20170341069-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | UNIV CALIFORNIA (US) | 2017-11-30 | — | — | US | disclosed |
| US-9758509-B2 | Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors | ALLERGAN, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9717714-B2 | Spirocyclic CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-01 | — | — | US | disclosed |
| WO-2017078927-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
| US-7205080-B2 | Arylamine compound, charge transport material, electrophotographic photoreceptor, image forming apparatus and process cartridge | FUJI XEROX CO., LTD. (JP) | 2007-04-17 | — | — | US | disclosed |
| WO-2007000550-A2 | NOVEL INDOLINE COMPOUNDS | LABORATOIRES FOURNIER S.A. (FR) | 2007-01-04 | — | — | WO | disclosed |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2006-08-03 | — | — | US | disclosed |
| EP-1684694-A2 | AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1663201-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-06-07 | — | — | EP | disclosed |
| EP-1626961-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | Korea Research Institute of Bioscience and Biotechnology (KR) | 2006-02-22 | — | — | EP | disclosed |
| WO-2005051304-A2 | AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005004861-A1 | A USE OF NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004101523-A1 | NOVEL 2-OXO-HETEROCYCLIC COMPOUNDS AND THE PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | L3MBTL1 3947/4885LMNA 1809/4885MAPT 1687/4885 |
| US-20060173043-A1 | Use of novel 2-oxo-heterocyclic compounds and the pharmaceutical compositions comprising the same | MALT1, BRCA1, MCL1 | L3MBTL1 1147/4885LMNA 3406/4885MAPT 4868/4885 |
| US-20170341069-A1 | NANO-TO-NANO FE/PPM Pd CATALYSIS OF CROSS-COUPLING REACTIONS IN WATER | SOD1, MPO, TFRC | L3MBTL1 2922/4885LMNA 4670/4885MAPT 2908/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.